K2bio is a hybrid Contract Research Organization, offering our partners the option to conduct their own research studies in our bio-accelerator facility or contract our industry-experienced scientists to design and execute studies on their behalf.

Our unique bench to commercialization model closes the gap between preclinical studies and clinical application. K2bio services includes GLP and non-GLP in vivo and in vitro support, analytical development, research and development support, and scale up for product commercialization, all tailored to client needs and goals.

We offer a flexible suite of services to help our partners transition today’s scientific discovery into tomorrow’s therapies by creating efficiencies in early-stage development and navigating barriers to maximize productivity and minimize R&D spending.